Par Pharm Company Profile

✉ Email this page to a colleague

PAR PHARM has one hundred and fifty-three approved drugs.

There is one US patent protecting PAR PHARM drugs. There are thirteen tentative approvals on PAR PHARM drugs.

There are nine patent family members on PAR PHARM drugs in eight countries and one hundred and ninety supplementary protection certificates in fifteen countries.

International Patents:	9
US Patents:	1
Tradenames:	98
Ingredients:	96
NDAs:	153
Patent Litigation for Par Pharm:	See patent lawsuits for Par Pharm
PTAB Cases with Par Pharm as petitioner:	See PTAB cases with Par Pharm as petitioner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Par Pharm	EVEROLIMUS	everolimus	TABLET;ORAL	207934-002	Dec 9, 2019	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Par Pharm	TRICHLORMETHIAZIDE	trichlormethiazide	TABLET;ORAL	087007-001	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Par Pharm	BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE	bismuth subcitrate potassium; metronidazole; tetracycline hydrochloride	CAPSULE;ORAL	205770-001	Mar 6, 2023	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
Par Pharm	LEUCOVORIN CALCIUM	leucovorin calcium	TABLET;ORAL	071598-001	Oct 14, 1987		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Par Pharm	NIFEDIPINE	nifedipine	TABLET, EXTENDED RELEASE;ORAL	077899-001	Dec 13, 2006		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Par Pharm	NASCOBAL	cyanocobalamin	GEL, METERED;NASAL	019722-001	Nov 5, 1996	4,724,231	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Nasal Spray	500 mcg/spray	➤ Subscribe	2017-04-28

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2269603	122015000094	Germany	⤷ Try a Trial	PRODUCT NAME: EVEROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/09/538/001 20120723
2330892	SPC/GB17/001	United Kingdom	⤷ Try a Trial	PRODUCT NAME: GLYCEROL PHENYLBUTYRATE; REGISTERED: UK EU/1/15/1062 20151201; UK PLGB53487/0001 20151201
0240228	C980022	Netherlands	⤷ Try a Trial	PRODUCT NAME: QUETIAPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAAR DBAAR ZOUT, IN HET BIJZONDER QUETIAPINEFUMARAAT; NAT. REGISTRATION NO/DATE: RVG 20826 - RVG 20828 19980427; FIRST REGISTRATION: GB PL 12619/0112 - PL 12619/0114 19970731
2822954	LUC00083	Luxembourg	⤷ Try a Trial	PRODUCT NAME: BICTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR BICTEGRAVIR SODIUM; AUTHORISATION NUMBER AND DATE: EU/1/18/1289 20180625
2236132	92636	Luxembourg	⤷ Try a Trial	PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.